🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Steven Cohen’s PLSE Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+106,457 Shares
Current Position
106,457 Shares
$2.95 M Value

Steven Cohen's PLSE Position Overview

Steven Cohen (via Point72 Asset Management, L.P.) currently holds 106,457 shares of Pulse Biosciences, Inc. (PLSE) worth $2.95 M, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Steven Cohen has initiated a new position in PLSE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Steven Cohen's Pulse Biosciences (PLSE) Holding Value Over Time

Track share changes against reported price movement

Quarterly Pulse Biosciences (PLSE) Trades by Steven Cohen

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +106,457 New Buy 106,457 $27.73

Steven Cohen's Pulse Biosciences Investment FAQs

Steven Cohen first purchased Pulse Biosciences, Inc. (PLSE) in Q2 2026, acquiring 106,457 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Steven Cohen has held Pulse Biosciences, Inc. (PLSE) for 1 quarters since Q2 2026.

Steven Cohen's largest addition to Pulse Biosciences, Inc. (PLSE) was in Q2 2026, adding 106,457 shares worth $2.95 M.

According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 106,457 shares of Pulse Biosciences, Inc. (PLSE), valued at approximately $2.95 M.

As of the Q2 2026 filing, Pulse Biosciences, Inc. (PLSE) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.

Steven Cohen's peak holding in Pulse Biosciences, Inc. (PLSE) was 106,457 shares, as reported at the end of Q2 2026.